Suppr超能文献

溴隐亭治疗中枢性发热的退热疗效:一项探索性分析。

Antipyretic Efficacy of Bromocriptine in Central Fever: an Exploratory Analysis.

机构信息

Department of Pharmacy, Texas Health Presbyterian Hospital, Dallas, TX, USA.

Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA.

出版信息

Neurocrit Care. 2023 Oct;39(2):499-504. doi: 10.1007/s12028-023-01703-7. Epub 2023 Mar 25.

Abstract

BACKGROUND

'Central' fevers are thought to result from disruption of hypothalamic thermoregulatory pathways following severe brain injuries. Bromocriptine, due to its central dopamine receptor agonism, has been hypothesized to have antipyretic effect in this setting. However, clinical evidence for this off-label use is limited to a few case reports. In this retrospective cohort study, we analyzed the effect of bromocriptine administration on body temperature in acute brain injury patients with suspected central fever.

METHODS

We screened a cohort of adult patients that received bromocriptine in the neurologic-intensive care unit of a tertiary care hospital between January 2018 and December 2021. Indication of central fever was ascertained by review of clinical documentation. A generalized additive mixed model (GAMM) was used to model temperature as a function of time relative to bromocriptine initiation. We adjusted for potential confounding due to the following covariates: temperature recording method (invasive vs surface), concurrent antipyretic administration within 8 h, and surface cooling device use within 4 h of temperature measurement. Temperature-time function was modeled using a cubic spline with k = 10 knots.

RESULTS

A total of 33 patients were included in the analysis (14 women; mean age: 50 y, standard deviation 14 y). Median dose of bromocriptine was 7.5 mg (range 2.5-40) for a median of 13 d (range 5-160). Age and sex did not impact the function of temperature over time. Predicted temperatures were significantly (p < 0.05) higher by 0.4 °C with invasive compared to surface recording methods, lower by 0.2 °C in the presence of cooling device use and lower by 0.1 °C with concurrent antipyretic use. On adjusted analysis with the GAMM, there was decline (p < 0.05) in temperature following bromocriptine initiation by - 0.3 °C at 24 h, - 0.5 °C at 48 h, and - 0.7 °C at 72 h.

CONCLUSIONS

Bromocriptine use was associated with modest but statistically significant decline in temperature, with nadir at 72 h post initiation. The findings provide a data driven basis for prospective evaluation.

摘要

背景

人们认为,严重脑损伤后下丘脑体温调节通路的破坏会导致“中枢性”发热。由于溴隐亭具有中枢多巴胺受体激动作用,因此有人假设它在这种情况下具有解热作用。然而,这种非适应证使用的临床证据仅限于少数病例报告。在这项回顾性队列研究中,我们分析了溴隐亭给药对疑似中枢性发热的急性脑损伤患者体温的影响。

方法

我们筛选了 2018 年 1 月至 2021 年 12 月期间在一家三级医院的神经重症监护病房接受溴隐亭治疗的成年患者队列。通过审查临床记录确定中枢性发热的指征。使用广义加性混合模型 (GAMM) 来模拟体温与溴隐亭给药开始后时间的关系。我们通过以下协变量进行了潜在混杂因素的调整:体温记录方法(侵入性与表面性)、8 小时内同时使用解热药和体温测量后 4 小时内使用表面冷却装置。使用具有 10 个节点的三次样条函数对温度-时间函数进行建模。

结果

共有 33 名患者纳入分析(14 名女性;平均年龄 50 岁,标准差 14 岁)。溴隐亭的中位剂量为 7.5mg(范围 2.5-40),中位治疗时间为 13 天(范围 5-160)。年龄和性别对随时间变化的体温功能没有影响。与表面记录方法相比,侵入性记录方法的预测温度平均高 0.4°C,使用冷却装置时低 0.2°C,同时使用解热药时低 0.1°C。在使用 GAMM 进行调整分析后,溴隐亭给药后 24 小时、48 小时和 72 小时的体温分别下降(p<0.05)0.3°C、0.5°C 和 0.7°C。

结论

溴隐亭的使用与体温适度但有统计学意义的下降相关,在给药后 72 小时达到最低值。这些发现为前瞻性评估提供了数据支持。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验